AP
|
Neubauer Artists LLC Getting your Trinity Audio player ready... |
An Abbott spokesman said generic drugs with brand names are preferred in many developing markets due to their reputation for quality and consistent supply.
CFR Pharmaceuticals, which is based in Chile, sells more than 1,000 products in 15 Latin American markets. Abbott expects the deal to add about $900 million in revenue in 2015, the first full year after it is completed.
Abbott will buy the holding company that indirectly owns about 73 percent of CFR and then will conduct a cash tender offer for the remaining shares. The deal value tops $3 billion when counting about $430 million in debt.
Abbott will use cash to pay for the deal, which will have no impact on its 2014 earnings forecast. The drugmaker expects to close the acquisition by the end of the third quarter.
According to Abbot Laboratories Director
Jorge Garcia is currently employed by Abbott Laboratories – Abbott Vascular, as Senior Director of Business Excellence. At Abbott Nutrition, as Commercial Initiatives Director, he led the digital transformation, establishing online commercialization channels, creating and driving CRM retention programs, conducting organizational change management, and designing and deploying new technical capabilities to establish a Consumer and HCP Centric Business mentality. He was the General Manager for Central America and the Dominican Republic, in 2017. Where he led the business turnaround, led organizational change, set the new commercial foundations for accelerated growth, and devised a medium-term growth path for this business.
Jorge successfully led the dual business transformation at Abbott Diabetes Care in Europe by setting the commercial Direct to Patient Go to Market business model across the region for the launch of “FreeStyle Libre”, a revolutionary glucose monitoring platform. He also held the position of General Manager for Latin America, where he oversaw the commercialization, marketing, customer service, supply chain, regulatory, and quality aspects. He initiated several sales force expansions and spearheaded product launches that solidified Abbott’s presence in the device arena. He has held various positions in general management for Abbott’s diabetes business since 2002.
He received a B.Sc. in Economics from the London School of Economics and his MBA from Kellogg Graduate School of Management.
Source: Associated Press
About The Author
